WuXi Biologics (Cayman) Inc. (2269.HK) HKSE

35.60

+0.44(+1.25%)

Updated at October 20 09:41AM

Currency In HKD

Valuation

Market Cap67.32B
Enterprise Value63.98B
P/E Ratio32.58
PEG Ratio1.15
Price/Sales Ratio6.54
Price/Book Ratio3.04
Enterprise/Revenue6.38
Enterprise/EBITDA17.26

Fiscal Year

Fiscal YearDecember 31, 2024
Most Recent QuarterJune 30, 2025

Profitability

Profit Margin0.21
Operating Margin0.29

Management Effectiveness

Return On Assets0.07
Return On Equity0.1

Income Statement

Revenue18.68B
Revenue/Share4.73
Gross Profit7.65B
EBITDA6.43B
Net Income3.36B
Diluted EPS0.78

Balance Sheet

Total Cash12.54B
Total Cash/Share2.73
Total Debt5.11B
Total Debt/Equity0.11
Current Ratio2.88
Book Value Per Share11.57

Price History

52-Week Change115.18
52-Week High42.6
52-Week Low14.14
Moving Average 50 Days35.88
Moving Average 200 Days26.76

Statistics

Average Volume53.63M
Shares Outstanding4.07B
% Held by Institutions0.07

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor3:1
Last Split DateNovember 30, 2020